Charcot-Marie-Tooth
disease (CMT) refers to a group of inherited neurological disorders that cause
damage to the peripheral nerves. Symptoms include leg and foot weakness and
deformities, foot drop, high foot arches, and trouble walking. As there is no
cure for CMT, treatment aims to manage symptoms and improve quality of life.
The global Charcot-Marie-Tooth disease market is estimated to be valued at US$
1392.68 Mn in 2024 and is expected to exhibit a CAGR of 3.6% over the forecast
period 2024 to 2031.
Key Takeaways
Key players operating in the Charcot-Marie-Tooth disease are Baxter, AbbVie
Inc., Piramal Enterprises Ltd., Fresenius SE & Co. KgaA, Drägerwerk AG
& Co. KgaA, GE Healthcare, and Mindray Medical International Limited, among
others. The increasing investments in R&D and growing awareness regarding
CMT disease present significant opportunities in the market. Additionally, expanding
healthcare infrastructure and growing geriatric population in developing
regions are fueling the global expansion of the CMT disease market.
Market Drivers
The key driver for the
Charcot-Marie-Tooth
Disease Market Growth is the increasing funding for research on CMT
disease. Several nonprofit organizations are funding research to better
understand the genetic causes and develop therapies. For instance,
Charcot-Marie-Tooth Association invested $2.8 million in research funding in
2022, which is expected to aid the development of new treatment approaches and
drive the market growth over the forecast period.
PEST
Analysis
Political: Government regulations on clinical trials and drug approvals along
with reimbursement policies will impact the market growth.
Economic: Rising healthcare expenditures and increasing disposable incomes will
drive the demand for advanced treatment options.
Social: Growing awareness about rare diseases and availability of supporting
community organizations will influence the patients to seek proper treatment.
Technological: Developments in genetic testing and innovations in gene therapy
are expected to offer new treatment avenues in the forecast period. Continuous
research also aims to improve current treatment standards.
The North American region currently dominates the Charcot-Marie-Tooth disease
market in terms of value. This can be attributed to factors such as the growing
healthcare expenditure, rising incidence of the disease, developing
reimbursement framework, and presence of major industry players in the region.
The Asia Pacific region is poised to witness the fastest growth over the coming
years. Elements like the large patient pool, increasing healthcare awareness,
and improving access to diagnosis and care are fueling the market expansion in
Asia Pacific.
Europe captured the second largest share of the global market in 2024 due to
the rising initiatives to support rare disease research. Countries like
Germany, France, and the UK have a considerable patient population and hold
prominent research centers that are actively working on CMT therapeutics. This
is strengthening the regional market. However, limited awareness in developing
nations still poses a challenge.
Get
more insights on – Charcot-Marie-Tooth
Disease Market
Explore
Related Articles- Biopharmaceuticals
Market
About Author:
Ravina Pandya, Content Writer, has a strong foothold
in the market research industry. She specializes in writing well-researched
articles from different industries, including food and beverages, information
and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Comments
Post a Comment